Migraine: Causes, Red Flags, Treatment & When to See a Doctor

## Overview Migraine is a complex, recurrent neurological disorder characterized by moderate-to-severe headache — typically unilateral and pulsating — often accompanied by nausea, vomiting, and heightened sensitivity to light (photophobia) and sound (phonophobia). It is classified under ICD-10 code **G43** and represents one of the most prevalent and disabling conditions worldwide. According to the Global Burden of Disease Study (GBD 2016), migraine is the second-leading cause of years lived with disability globally, affecting approximately **1 billion people** across all age groups (PMID:28919117) [1]. In the United States, epidemiological data indicate that roughly **15–18% of women** and **6–8% of men** experience migraine in any given year (PMID:25600719) [4]. Peak prevalence occurs between the ages of 25 and 55, coinciding with the most productive working years. People search for information about migraine for several reasons: to distinguish migraine from other headache types, to identify warning signs that require urgent care, to find effective relief strategies, and to understand when prescription-level treatment is warranted. This article provides a comprehensive, evidence-based overview of migraine — its causes, treatments, and the critical red flags that should never be ignored. Migraine is not simply a "bad headache." It is a spectrum disorder with distinct phases — **prodrome** (hours to days before), **aura** (in ~25–30% of patients), **headache phase**, and **postdrome** — each reflecting different underlying neurobiological processes. Understanding this complexity is key to effective management. ## Common Causes Migraine pathophysiology involves a cascade of neurological and vascular events. Research over the past two decades has shifted understanding away from a purely vascular model toward a **neurovascular framework** centered on abnormal brain excitability and trigeminovascular system activation (PMID:28179394) [2]. ### 1. Genetic Predisposition (Most Common Factor) Migraine has a strong hereditary component. Twin studies suggest **heritability of 42–57%**. Multiple gene variants — including those affecting ion channels (e.g., *CACNA1A*, *SCN1A*), neurotransmitter pathways, and vascular function — contribute to migraine susceptibility. Having a first-degree relative with migraine increases one's risk significantly. ### 2. Trigeminovascular Activation The trigeminovascular system — comprising trigeminal nerve fibers innervating meningeal blood vessels — is central to migraine pain. Activation of these sensory fibers releases vasoactive neuropeptides, particularly **calcitonin gene-related peptide (CGRP)**, substance P, and neurokinin A, which promote neurogenic inflammation and vasodilation of dural blood vessels (PMID:28179394) [2]. ### 3. Cortical Spreading Depression (CSD) CSD is a slowly propagating wave of neuronal and glial depolarization across the cortex, followed by prolonged suppression of neural activity. It is the accepted physiological substrate of **migraine aura** and may also trigger headache by activating meningeal nociceptors even in patients without clinical aura (PMID:33211930) [3]. ### 4. Central Sensitization Repeated trigeminovascular activation can lead to central sensitization — a state in which second- and third-order neurons in the brainstem and thalamus become hyperexcitable. This explains **cutaneous allodynia** (pain from normally non-painful stimuli such as combing hair) and the escalation from episodic to chronic migraine. ### 5. Common Triggers While triggers do not cause migraine, they can precipitate attacks in susceptible individuals. Evidence-supported triggers include: - **Hormonal fluctuations** — estrogen withdrawal (menstruation, perimenopause) is the single most consistent trigger in women - **Stress and post-stress let-down** ("weekend migraine") - **Sleep disruption** — both deprivation and oversleeping - **Dietary factors** — alcohol (especially red wine), aged cheeses, MSG, caffeine withdrawal, skipped meals - **Environmental stimuli** — bright or flickering lights, strong odors, barometric pressure changes - **Medication overuse** — using acute headache medications ≥10–15 days/month can paradoxically worsen migraine frequency (medication-overuse headache) ### 6. Serotonin Dysregulation Altered serotonin (5-HT) metabolism plays a role in migraine. Platelet serotonin levels drop during attacks, and triptans — highly effective acute treatments — work by activating 5-HT₁B/₁D receptors. This supports the involvement of serotonergic pathways in migraine modulation. ## RED FLAGS Most migraines, while debilitating, are not dangerous. However, certain features — sometimes summarized by the mnemonic **SNOOP4** — indicate potentially life-threatening conditions that mimic or coexist with migraine. **Seek emergency medical attention (ER/911) immediately** if you experience: - **"Thunderclap" headache** — the worst headache of your life reaching maximum intensity within seconds to minutes (may indicate subarachnoid hemorrhage) - **New headache with fever, neck stiffness, and rash** — possible meningitis or encephalitis - **Headache with focal neurological deficits** that do not resolve within 60 minutes — weakness on one side, speech difficulty, vision loss (possible stroke) - **New-onset headache after age 50** — raises concern for giant cell arteritis, intracranial mass, or other secondary causes - **Headache with papilledema** (swelling of the optic disc) — suggests raised intracranial pressure - **Progressive headache worsening over days to weeks** despite treatment — possible space-occupying lesion - **Headache triggered by coughing, exertion, or Valsalva maneuver** — may indicate Chiari malformation or intracranial lesion - **New headache in a patient with cancer, HIV, or immunosuppression** — risk of CNS infection or metastasis - **Headache following head trauma** — possible subdural or epidural hematoma - **Aura symptoms that are always on the same side** or include motor weakness — may indicate hemiplegic migraine or structural lesion requiring imaging - **Seizure occurring with headache** > **Important:** If you have an established migraine pattern and your current attack feels different — more severe, longer-lasting, or with new symptoms — treat it as a red flag and seek medical evaluation promptly. ## Self-Care at Home Non-pharmacological strategies form a critical component of migraine management. Several approaches have evidence supporting their use. ### During an Acute Attack - **Rest in a quiet, dark room** — reducing sensory stimulation can help limit symptom severity - **Cold application** — applying a cold pack to the forehead or temples for 15–20 minutes may reduce pain intensity. A small randomized trial showed benefit from frozen neck wraps applied at headache onset - **Hydration** — dehydration is a recognized trigger; adequate fluid intake during an attack is advisable - **Caffeine in small amounts** — 65–200 mg caffeine may enhance analgesic efficacy (it is an adjuvant in several OTC combination products), but regular use risks medication-overuse headache ### Preventive Lifestyle Measures - **Regular sleep schedule** — maintaining consistent bed and wake times, even on weekends, is one of the most consistently recommended behavioral interventions (PMID:25600718) [6] - **Aerobic exercise** — moderate-intensity aerobic exercise (e.g., 30–40 minutes, 3–5 times per week) has been shown in randomized trials to reduce migraine frequency comparably to topiramate prophylaxis - **Stress management** — cognitive behavioral therapy (CBT), mindfulness-based stress reduction (MBSR), and biofeedback have demonstrated efficacy in migraine prevention. Biofeedback (thermal and EMG) carries a Grade A evidence rating from the American Academy of Neurology - **Dietary regularity** — avoiding prolonged fasting, maintaining regular mealtimes, and identifying personal food triggers through diary tracking - **Trigger diary** — keeping a headache diary to record attack frequency, severity, duration, triggers, and medication use. This is invaluable for clinical assessment and treatment optimization - **Magnesium supplementation** — oral magnesium (400–600 mg/day of magnesium oxide or citrate) may reduce migraine frequency, particularly in patients with aura. Evidence is moderate but supportive (PMID:22529202) [5] - **Riboflavin (vitamin B2)** — 400 mg/day has shown benefit in migraine prevention in a placebo-controlled trial, with a favorable safety profile - **Coenzyme Q10** — 100 mg three times daily may help reduce attack frequency, based on limited but positive trial data ## OTC Medications That Help Over-the-counter analgesics are appropriate first-line treatment for mild-to-moderate migraine attacks. The American Headache Society evidence assessment supports the use of several OTC agents (PMID:25600718) [6]. | Class | Example | Typical Adult Dose | Notes | |---|---|---|---| | **NSAIDs** | Ibuprofen | 400–600 mg at onset, may repeat q6–8h (max 1200 mg/day for self-care) | First-line OTC option. Take early in the attack for best results. Avoid in renal impairment, active GI ulcers, or third trimester of pregnancy. | | **NSAIDs** | Naproxen sodium | 500–550 mg at onset, may repeat 250 mg q12h (max 750 mg/day) | Longer duration of action than ibuprofen. Same GI and renal precautions. | | **NSAIDs** | Aspirin | 900–1000 mg at onset | Evidence-based dose for migraine. Avoid in children/teens (Reye syndrome risk), bleeding disorders, aspirin-sensitive asthma. | | **Analgesic** | Acetaminophen (paracetamol) | 1000 mg at onset (max 3000–4000 mg/day) | Less effective than NSAIDs for moderate migraine but useful when NSAIDs are contraindicated. Avoid exceeding daily limits; hepatotoxicity risk with overuse or alcohol consumption. | | **Combination** | Aspirin + Acetaminophen + Caffeine (e.g., Excedrin Migraine) | 2 tablets (250 mg ASA + 250 mg APAP + 65 mg caffeine per tablet) | FDA-approved OTC migraine treatment. Caffeine enhances analgesic absorption and efficacy. Limit use to ≤2 days/week to avoid medication-overuse headache. | | **Antiemetic** | Dimenhydrinate | 50–100 mg q4–6h (max 400 mg/day) | Addresses nausea/vomiting component. May cause drowsiness. | **Key principles for OTC use:** - **Treat early** — take medication at the first sign of migraine, before pain escalates and central sensitization develops - **Adequate dose** — underdosing is a common reason for OTC failure - **Limit frequency** — using acute medications (OTC or prescription) on ≥10–15 days/month can lead to medication-overuse headache (MOH) - **Antiemetics first if vomiting** — oral medications are poorly absorbed during migraine-associated gastroparesis; consider an antiemetic 15–20 minutes before analgesic ## Prescription Options Prescription treatment for migraine falls into two categories: **acute (abortive)** therapy and **preventive (prophylactic)** therapy. A neurologist or primary care physician typically manages these medications. ### Acute (Abortive) Prescription Treatments | Class | Example(s) | Route / Dose | Notes | |---|---|---|---| | **Triptans** (5-HT₁B/₁D agonists) | Sumatriptan, rizatriptan, eletriptan, zolmitriptan | Sumatriptan 50–100 mg PO, 6 mg SC, or 20 mg nasal | Gold standard for moderate-to-severe migraine. Contraindicated in uncontrolled hypertension, coronary artery disease, stroke, and peripheral vascular disease. Should not be used within 24 hours of ergots. | | **Gepants** (CGRP receptor antagonists) | Ubrogepant, rimegepant | Ubrogepant 50–100 mg PO; rimegepant 75 mg ODT | Newer class; useful when triptans are contraindicated or ineffective. No vasoconstrictive properties. Rimegepant is also approved for prevention (every other day dosing). | | **Ditans** (5-HT₁F agonists) | Lasmiditan | 50–200 mg PO | No vasoconstrictive effects — can be used with cardiovascular disease. Causes dizziness/sedation; patients should not drive for 8 hours after dosing. DEA Schedule V. | | **Ergotamines** | Dihydroergotamine (DHE) | 1 mg IV/IM/SC or nasal spray | Effective for prolonged attacks and status migrainosus. Contraindicated in cardiovascular disease and pregnancy. Not for frequent use. | | **Antiemetics** (dopamine antagonists) | Metoclopramide, prochlorperazine | Metoclopramide 10 mg IV/PO; prochlorperazine 10 mg IV/PO | Useful as monotherapy or adjunct. Prochlorperazine IV is a first-line treatment in ER settings. | | **Corticosteroids** | Dexamethasone | 4–8 mg IV (single dose) | Adjunctive use in ER to reduce headache recurrence within 72 hours. Not for routine use. | ### Preventive Prescription Treatments Prevention is generally recommended when migraine occurs **≥4 days per month**, significantly impairs function, or when acute treatments are contraindicated or overused (PMID:22529202) [5]. | Class | Example(s) | Typical Dose | Notes | |---|---|---|---| | **Beta-blockers** | Propranolol, metoprolol | Propranolol 40–240 mg/day | First-line preventive. Avoid in asthma, decompensated heart failure. May cause fatigue and exercise intolerance. | | **Antiepileptics** | Topiramate, valproate | Topiramate 50–100 mg/day; valproate 500–1500 mg/day | Strong evidence base. Topiramate may cause cognitive dulling and weight loss; valproate is **teratogenic** (contraindicated in pregnancy or women of childbearing potential without contraception). | | **Antidepressants** | Amitriptyline, venlafaxine | Amitriptyline 10–75 mg at bedtime | Particularly useful when migraine coexists with tension-type headache or insomnia. Anticholinergic side effects. | | **CGRP monoclonal antibodies** | Erenumab, fremanezumab, galcanezumab, eptinezumab | Erenumab 70–140 mg SC monthly | Targeted therapy; generally well tolerated. Erenumab targets the CGRP receptor; others target the CGRP ligand. Eptinezumab is IV (quarterly). | | **Gepants (preventive)** | Rimegepant, atogepant | Atogepant 30–60 mg/day PO; rimegepant 75 mg every other day | Oral CGRP pathway antagonists with dual acute/preventive potential. | | **OnabotulinumtoxinA** | Botox | 155–195 units IM q12 weeks | FDA-approved specifically for **chronic migraine** (≥15 headache days/month). Administered by a trained specialist. | | **Neuromodulation devices** | sTMS, eTNS, nVNS, REN | Varies by device | Non-pharmacological prescription options. FDA-cleared devices include single-pulse TMS (SpringTMS), external trigeminal nerve stimulation (Cefaly), non-invasive vagus nerve stimulation (gammaCore), and remote electrical neuromodulation (Nerivio). | ## Lab Tests Typically Ordered Migraine is a **clinical diagnosis** — there is no specific lab test or imaging study that confirms migraine. However, tests may be ordered to exclude secondary causes, assess comorbidities, or guide safe prescribing. | Test | Rationale | |---|---| | [Complete blood count (CBC)](/tests/complete-blood-count) | Rule out anemia or infection as headache contributors | | [Erythrocyte sedimentation rate (ESR)](/tests/esr) and [C-reactive protein (CRP)](/tests/c-reactive-protein) | Elevated in giant cell arteritis (especially in patients >50 with new headache) | | [Thyroid function tests (TSH)](/tests/thyroid-function-tests) | Thyroid dysfunction can exacerbate or mimic headache disorders | | [Basic metabolic panel (BMP)](/tests/basic-metabolic-panel) | Assess electrolytes and renal function, especially before prescribing NSAIDs or certain preventives | | [Liver function tests](/tests/liver-function-tests) | Baseline before starting valproate or other hepatically metabolized preventives | | [Magnesium level](/tests/magnesium) | Hypomagnesemia is associated with migraine; may guide supplementation | | [MRI brain with/without contrast](/tests/mri-brain) | Not routine for typical migraine but indicated for atypical features, new neurological signs, or red flag symptoms | | CT head (non-contrast) | Urgent imaging for thunderclap headache to rule out subarachnoid hemorrhage | | Lumbar puncture | If meningitis, idiopathic intracranial hypertension, or low-CSF-pressure headache is suspected (after imaging) | ## Special Populations ### Children and Adolescents Migraine affects approximately **8–10% of school-age children**. Pediatric migraine often presents differently from adult migraine: - Attacks may be shorter (as brief as 2 hours, vs. 4 hours minimum in adults) - Pain is more often bilateral (frontal or temporal) rather than unilateral - Gastrointestinal symptoms (abdominal pain, nausea) may be prominent — "abdominal migraine" is a recognized pediatric variant **Treatment considerations:** - Ibuprofen and acetaminophen are first-line acute treatments in children, but **dosing must be weight-based and determined by a pediatric clinician** - Among triptans, almotriptan (≥12 years) and rizatriptan (≥6 years) have FDA approval for pediatric use - Preventive medications in children should generally be managed by a pediatric neurologist. Evidence for most preventive agents in pediatrics is limited; the CHAMP trial found topiramate and amitriptyline were not superior to placebo in pediatric migraine prevention - Behavioral interventions (CBT, biofeedback) carry strong evidence in pediatric migraine and are generally preferred as first-line prevention ### Pregnancy Migraine — particularly migraine without aura — often **improves during pregnancy**, especially in the second and third trimesters, likely due to stable estrogen levels. However, some women experience worsening or new-onset migraine. **Treatment considerations:** - **Acetaminophen** is the preferred acute analgesic (generally considered compatible with pregnancy in all trimesters) - **NSAIDs** should be avoided after 20 weeks of gestation (risk of premature closure of ductus arteriosus and oligohydramnios; FDA safety communication 2020) [7] - **Triptans**: Sumatriptan has the most pregnancy exposure data. Registry data have not shown a clear increase in major birth defects, but triptans are generally used only when benefit outweighs risk, in consultation with an obstetrician - **Ergotamines** are **contraindicated** in pregnancy (uterotonic effects) - **Valproate** is **absolutely contraindicated** in pregnancy (high teratogenic risk — neural tube defects, developmental delay) - For prevention, **propranolol** or **low-dose amitriptyline** may be considered when non-pharmacological approaches are insufficient - **CGRP-targeting therapies** (monoclonal antibodies and gepants) lack adequate pregnancy safety data; discontinuation is generally recommended before conception or upon confirmation of pregnancy - Non-pharmacological strategies (regular sleep, hydration, stress management, acupuncture) should be maximized ### Elderly (≥65 Years) - New-onset migraine is uncommon after age 50 — always evaluate for secondary causes (giant cell arteritis, intracranial pathology) - Triptans carry increased cardiovascular risk in the elderly; gepants or lasmiditan may be safer alternatives - Preventive medications require careful dose titration due to comorbidities and polypharmacy. Beta-blockers may worsen bradycardia or orthostatic hypotension; tricyclic antidepressants carry anticholinergic burden (confusion, urinary retention, falls) - NSAIDs should be used sparingly due to heightened GI bleeding and renal impairment risk - CGRP monoclonal antibodies appear to have a favorable safety profile in older adults, though trial data in this age group are limited ### Athletes - **Exercise-triggered migraine** is common and should be distinguished from primary exertional headache and cardiac cephalgia - Adequate hydration, gradual warm-up, and avoiding exercising in extreme heat may reduce exercise-triggered attacks - Beta-blockers may impair athletic performance (reduced heart rate reserve, exercise intolerance); CGRP monoclonal antibodies or neuromodulation devices may be preferable preventive options - Athletes in organized sports should be aware that some migraine medications may appear on anti-doping prohibited lists (e.g., certain beta-blockers in precision sports); consult sports medicine guidance - Post-concussive headache can mimic or exacerbate migraine — any new or worsening headache after head injury in an athlete requires proper concussion evaluation and return-to-play protocol ## When to Escalate Use the following guide to determine the appropriate level of care: ### Same-Day GP / Primary Care Visit - Migraine that is **not adequately controlled** by OTC medications - Migraine occurring **≥4 days per month** or increasing in frequency - Need for a **prescription acute treatment** (triptans, gepants) or discussion of prevention - Migraine with new or unfamiliar **aura symptoms** (e.g., first-ever visual aura) - Concern about **medication-overuse headache** (using acute treatments ≥10–15 days/month) ### Urgent Care / Same-Day Evaluation - Migraine lasting **>72 hours** despite appropriate acute treatment (status migrainosus) - Migraine with **persistent vomiting** preventing oral medication and fluid intake (dehydration risk) - Migraine with **unusual or prolonged aura** (>60 minutes) - Migraine during **pregnancy** with new features ### Emergency Room / Call 911 - **Thunderclap headache** — sudden, severe headache reaching peak intensity within seconds - Headache with **fever, neck stiffness, confusion, or rash** - **New focal neurological deficits** — weakness, numbness, speech difficulty, vision loss — that do not follow a typical aura pattern or persist beyond 60 minutes - **First seizure** associated with headache - Headache after **head trauma**, especially with altered consciousness - Headache with **signs of elevated intracranial pressure** — papilledema, worsening with coughing/straining, positional component - Headache in a patient who is **immunocompromised, on anticoagulants, or has known malignancy** > **Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment of migraine or any medical condition. Individual treatment decisions should be made in partnership with your clinician based on your medical history, comorbidities, and preferences. ## References [1] GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet*. 2017;390(10100):1211-1259. PMID:28919117. [2] Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing. *Physiol Rev*. 2017;97(2):553-622. PMID:28179394. [3] Ashina M. Migraine. *N Engl J Med*. 2020;383(19):1866-1876. PMID:33211930. [4] Burch RC, Loder S, Loder E, Smitherman TA. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. *Headache*. 2015;55(1):21-34. PMID:25600719. [5] Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. *Neurology*. 2012;78(17):1337-1345. PMID:22529202. [6] Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. *Headache*. 2015;55(1):3-20. PMID:25600718. [7] U.S. Food and Drug Administration. FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid. FDA Drug Safety Communication. October 2020. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later. [8] National Institute for Health and Care Excellence (NICE). Headaches in over 12s: diagnosis and management. Clinical Guideline CG150. September 2012 (updated November 2021). Available at: https://www.nice.org.uk/guidance/cg150. [9] Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF; AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. *Neurology*. 2007;68(5):343-349. PMID:17261680.